Oncology

A new deal for the rare isotope Actinium-225 could break a major supply bottleneck, accelerating the development of highly targeted cancer treatments.

With its foundational drug a success, Madrigal bets billions on next-gen siRNA tech, aiming to fuse it with Rezdiffra and dominate MASH treatment.

Zelluna partners with Medpace for a first-in-human trial of its ZIMA-101 TCR-NK therapy, a new 'off-the-shelf' approach for hard-to-treat solid tumors.

A major new report reveals a deepening crisis in rural healthcare, as a $50 billion federal program clashes with devastating cuts, pushing a vital system to the brink.

AI genomics firm partners with two major US health systems, aiming to accelerate cancer and rare disease diagnostics for 60,000 patients annually.

New add-on tests from a single blood draw help oncologists avoid toxic chemo reactions and filter out false positives, aiming for safer, smarter cancer care.

Bolstered by a top regulatory expert and unique veterinary data, Vivos Inc. is set to file for human trials of its precision injectable cancer treatment.

Kincell Bio and RegCell partner to bring a groundbreaking, non-gene-edited Treg cell therapy for autoimmune diseases from the lab to clinical trials.

With two high-profile board appointments, Stellaromics signals its ambition to dominate the 3D spatial omics market with its advanced Pyxa™ platform.

Amid major restructuring and a strategic asset sale, Standard BioTools' upcoming annual results will reveal its progress toward profitability in a tough market.

Israeli startup Protai is set to reveal promising preclinical data for its cancer drug, PRT-001, powered by its unique proteomics-aware AI platform.

A groundbreaking partnership in Italy is creating an AI-powered biobank to transform cancer diagnosis, promising faster, more accurate results for patients.

Following a landmark FDA approval, IceCure Medical's long-serving CFO is exiting, placing the company at a pivotal financial crossroads for its new treatment.

AB Science's Masivet gets key FDA designation, paving the way for a new targeted cancer therapy for dogs and a major strategic win for the company.

A new pilot program uses AI to find hidden patterns in past cancer trial data, aiming to get the right drugs to the right patients, faster.

South Korean biotech Galux raises a major Series B round to accelerate its AI platform, which designs novel antibody drugs from scratch with high precision.

Bionano's 2026 virtual event will showcase how Optical Genome Mapping is revolutionizing cancer and genetic disease research and paving a path to clinical use.

A landmark deal will see Takeda use Iambic's AI platform to slash drug development timelines and fast-track new medicines for cancer and other diseases.

A groundbreaking dual-payload ADC from Kanghong Pharmaceutical has entered clinical trials, a major milestone in oncology accelerated by partner BioDlink.

IN8bio promotes Kate Rochlin to President, signaling a strategic push to advance its promising gamma-delta T cell pipeline amid a challenging market.